FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis

FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.

Fused in Sarcoma (FUS) is an RNA-binding protein implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)[@lagiertourenne2010]. Mutations in the FUS gene (also known as TLS - Translocated in Sarcoma) account for approximately 5-10% of familial ALS cases and are associated with aggressive, early-onset disease phenotypes[@kwiatkowski2009]. This page covers FUS biology, its role in ALS pathogenesis, and emerging therapeutic strategies targeting this pathway.

FUS Biology and Normal Function

Protein Structure

FUS (Fused in Sarcoma) is a 526-amino acid protein belonging to the FET (FUS, EWSR1, TAF15) family of RNA-binding proteins[@lagiertourenne2010]. The protein contains multiple functional domains:

FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.

Fused in Sarcoma (FUS) is an RNA-binding protein implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)[@lagiertourenne2010]. Mutations in the FUS gene (also known as TLS - Translocated in Sarcoma) account for approximately 5-10% of familial ALS cases and are associated with aggressive, early-onset disease phenotypes[@kwiatkowski2009]. This page covers FUS biology, its role in ALS pathogenesis, and emerging therapeutic strategies targeting this pathway.

FUS Biology and Normal Function

Protein Structure

FUS (Fused in Sarcoma) is a 526-amino acid protein belonging to the FET (FUS, EWSR1, TAF15) family of RNA-binding proteins[@lagiertourenne2010]. The protein contains multiple functional domains:

• N-terminal low-complexity (LC) domain: Involved in liquid-liquid phase separation and stress granule formation[@kato2012]
• RNA recognition motif (RRM): Binds RNA with sequence specificity[@lerga2001]
• Multiple zinc finger motifs: Mediates protein-protein interactions[@dormann2010]
• C-terminal prion-like domain: Facilitates aggregation propensity[@king2012]

Normal Cellular Functions

FUS participates in multiple essential cellular processes:

• RNA processing: Alternative splicing, transcription regulation, and RNA transport[@vance2009]
• DNA damage response: FUS recruitment to DNA damage sites[@britton2014]
• Stress granule formation: Phase-separated membraneless organelles that form under cellular stress[@li2013]
• Synaptic function: Local translation at synaptic terminals[@sephton2012]

FUS in ALS Pathogenesis

Genetic Evidence

Pathogenic FUS mutations were first identified in ALS in 2009[@kwiatkowski2009]. Over 50 mutations have been described, predominantly clustering in the C-terminal nuclear localization signal (NLS) region:

• P525L: Most common, associated with juvenile-onset ALS[@chio2012]
• R521C/G: Common variants with intermediate phenotype[@belzil2012]
• R514S/G: Associated with variable expressivity[@conte2012]

Pathogenic Mechanisms

Stress Granule Dysregulation

FUS normally localizes to stress granules under cellular stress. ALS-associated mutations lead to:

• Impaired stress granule dynamics: Altered assembly/disassembly kinetics[@dormann2010a]
• Persistent stress granules: Cytoplasmic FUS accumulation[@bentmann2012]
• Sequestration of translation machinery: Global translation inhibition[@kim2012]

RNA Metabolism Defects

FUS mutations disrupt normal RNA processing:

• Altered alternative splicing: Aberrant splicing patterns in ALS-relevant genes[@zhou2014]
• Mitochondrial dysfunction: RNA transport defects affect mitochondrial biogenesis[@deng2015]
• Axonal transport defects: RNA granules fail to reach synaptic terminals[@locatelli2013]

Liquid-Liquid Phase Separation

The low-complexity domain of FUS undergoes liquid-liquid phase separation (LLPS), which is disrupted by ALS mutations:

• Increased aggregation propensity: Mutant FUS forms irreversible aggregates[@murakami2015]
• Loss of membraneless organelle function: Stress granules become toxic[@patel2015]
• Seeding of endogenous FUS: Spreading of pathology to wild-type protein[@nonaka2015]

Clinical Phenotype

Disease Characteristics

FUS-associated ALS presents distinct clinical features:

• Early onset: Mean age of onset 40-45 years, compared to 55-65 for sporadic ALS[@rademakers2011]
• Rapid progression: Median survival 2-3 years from symptom onset[@ticozzi2011]
• Bulbar onset: Higher proportion of bulbar-onset compared to other genetic forms[@baek2011]
• Cognitive involvement: FTD co-occurrence in approximately 15% of cases[@lattante2013]

Phenotypic Spectrum

• ALS: Classical motor neuron disease presentation[@kwiatkowski2009]
• FTD: Frontotemporal dementia without motor symptoms[@van2012]
• ALS/FTD spectrum: Overlapping presentations[@tan2016]

Therapeutic Strategies

Gene Silencing Approaches

Antisense Oligonucleotides (ASOs)

ASOs targeting FUS mRNA are in development:

• Mechanism: RNase H-mediated degradation of mutant FUS transcripts[@bortone2019]
• Preclinical evidence: ASOs reduce mutant FUS expression and improve survival in mouse models[@korobeynikov2016]
• Clinical status: Investigational, no approved FUS-targeting ASO yet[@bhattacharya2022]

RNA Interference (RNAi)

• siRNA/shRNA approaches: Vectors delivering short hairpin RNAs[@schoch2016]
• Challenges: Delivery across [blood-brain barrier](/entities/blood-brain-barrier), off-target effects[@xia2015]

Small Molecule Approaches

Phase Separation Modulators

• Diclofenac: Identified in screen as LLPS modulator[@kim2019]
• 1,6-hexanediol: Dissolves stress granule-like structures[@wheeler2019]
• Status: Preclinical investigation[@zhang2020]

Antioxidants

• Edaravone: Approved ALS therapy with potential benefits in FUS-ALS[@jaiswal2019]
• CoQ10: Mitochondrial protection rationale[@orsini2011]

Neuroprotective Compounds

• Sodium phenylbutyrate/taurursodiol (Relyvrio): Approved ALS therapy, may have benefits[@paganoni2020]

Protein Clearance Enhancement

Autophagy Induction

• Rapamycin: [mTOR](/mechanisms/mtor-signaling-pathway) inhibition enhances autophagic clearance of mutant FUS[@chen2013]
• Trehalose: [Autophagy](/entities/autophagy) enhancer with preclinical evidence[@li2014]

Ubiquitin-Proteasome System

• Proteasome activators: Enhance clearance of misfolded FUS[@tashiro2012]

Symptomatic Management

• Riluzole: Standard of care, modest survival benefit[@bensimon1994]
• Edaravone: FDA-approved, selective for disease progression[@takei2017]
• Multidisciplinary care: Essential for quality of life[@chio2012a]

Biomarkers

Genetic Testing

• Confirmation of FUS mutation: Required for diagnosis[@strong2017]
• Family screening: At-risk relatives may benefit from genetic counseling[@benatar2017]

Fluid Biomarkers

• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Elevated in FUS-ALS, tracks progression[@lu2015]
• FUS levels in CSF: Potential for monitoring treatment response[@feneberg2017]

Neuroimaging

• MRI: Rule out mimics, monitor disease progression[@agosta2011]
• PET: Emerging tracers for neuroinflammation[@van2019]

Cross-Linking to Related Pathways

• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum): FUS-ALS represents a point on the ALS-FTD spectrum
• [Stress Granules in Neurodegeneration](/mechanisms/stress-granules-neurodegeneration): Central to FUS pathology
• [RNA Metabolism in Neurodegeneration](/rna-metabolism-in-neurodegeneration): Disrupted by FUS mutations
• [C9orf72-ALS/FTD](/mechanisms/dipeptide-repeat-proteins-c9orf72-als-ftd): Other major genetic cause of ALS-FTD

Research Directions

Clinical Trials

• ASO trials: Expected in coming years for FUS-ALS[@sarchielli2022]
• Biomarker studies: NfL as endpoint in clinical trials[@benatar2018]
• Natural history studies: Understanding disease progression[@chio2015]

Emerging Therapies

• CRISPR-based approaches: Gene editing of mutant FUS[@gaj2017]
• Stem cell models: Patient-derived iPSCs for drug screening[@sareen2013]
• Protein-protein interaction inhibitors: Targeting FUS aggregation[@ding2020]

Conclusion

FUS-associated ALS represents a distinct and aggressive subtype of motor neuron disease with unique pathogenesis centered on RNA metabolism and phase separation biology. While no FUS-specific therapies are currently approved, multiple approaches including ASOs, small molecules, and protein clearance enhancers are in development. Early genetic diagnosis and emerging clinical trials offer hope for patients with this challenging condition.

See Also

• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum)
• [Stress Granules in Neurodegeneration](/mechanisms/stress-granules-neurodegeneration)
• [RNA Metabolism in Neurodegeneration](/rna-metabolism-in-neurodegeneration)
• [C9orf72-ALS/FTD](/mechanisms/dipeptide-repeat-proteins-c9orf72-als-ftd)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: CSGA
• [Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting](/hypothesis/h-3a4f2027) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: HTT, DMPK, repeat-containing transcripts
• [Phase-Separated Organelle Targeting](/hypothesis/h-ec731b7a) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: G3BP1
• [Metabolic Switch Targeting for A1→A2 Repolarization](/hypothesis/h-a1b56d74) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: HK2
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
• [DNMT1-Targeting Antisense Oligonucleotide Reset](/hypothesis/h-782e55f6) — <span style="color:#ffd54f;font-weight:600">0.45</span> · Target: DNMT1

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;
• [CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) &#x1f504;
• [Microglial subtypes in neurodegeneration — friend vs foe](/analysis/SDA-2026-04-02-gap-microglial-subtypes-20260402004119) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;